Abstract:Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) gefitinib have shown dramatic effects against EGFR mutant lung cancer, patients become resistant by various mechanisms, including gatekeeper EGFR-T790M mutation, MET amplification, and KRAS mutation, thereafter relapsing. AZD6244 is a potent, selective, and orally available MEK1/2 inhibitor. In this study, we evaluated the therapeutic efficacy of AZD6244 alone or with BEZ235, an orally available potent inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in gefitinib-resistant non-small cell lung carcinoma (NSCLC) models.NCI-H1975 with EGFR-T790M mutation, NCI-H1993 with MET amplification and NCI-H460 with KRAS/PIK3CA mutation human NSCLC cells were subcutaneous injected into the athymic nude mice respectively. Mice were randomly assigned to treatment with AZD6244, BEZ235, AZD6244 plus BEZ235, or control for 3 weeks, then all mice were sacrificed and tumor tissues were subjected to western blot analyses and immunohistochemical staining.AZD6244 could inhibit the tumor growth of NCI-H1993, but slightly inhibit the tumor growth of NCI-1975 and NCI-H460. Combining AZD6244 with BEZ235 markedly enhanced their antitumor effects and without any marked adverse events. Western blot analysis and immunohistochemical staining revealed that AZD6244 alone reduced ERK1/2 phosphorylation, angiogenesis, and tumor cell proliferation. Moreover, MEK1/2 inhibition resulted in decreased AKT phosphorylation in NCI-H1993 tumor model. BEZ235 also inhibited AKT phosphorylation as well as their downstream molecules in all three tumor models. The antiangiogenic effects were substantially enhanced when the agents were combined, which may due to the reduced expression of matrix metallopeptidase-9 in tumor tissues (MMP-9).In this study, we evaluated therapy directed against MEK and PI3K/mTOR in distinct gefitinib-resistant NSCLC xenograft models. Combining AZD6244 with BEZ235 enhanced their antitumor and antiangiogenic effects. We concluded that the combination of a selective MEK inhibitor and a PI3K/mTOR inhibitor was effective in suppressing the growth of gefitinib-resistant tumors caused by EGFR T790M mutation, MET amplification, and KRAS/PIK3CA mutation. This new therapeutic strategy may be a practical approach in the treatment of these patients.

Dual PI3K/mTOR Inhibitor BEZ235 As a Promising Therapeutic Strategy Against Paclitaxel-Resistant Gastric Cancer Via Targeting PI3K/Akt/mTOR Pathway.

HMGA2 Promotes Resistance Against Paclitaxel by Targeting the P53 Signaling Pathway in Colorectal Cancer Cells

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Nab-Paclitaxel Antitumor Response in Experimental Gastric Cancer.

Dual PI3K/mTOR Inhibitor BEZ235 Exerts Extensive Antitumor Activity in HER2-positive Gastric Cancer

Dual PI3K/mTOR Inhibitor PF-04979064 Regulates Tumor Growth in Gastric Cancer and Enhances Drug Sensitivity of Gastric Cancer Cells to 5-FU

A Phase Ii, Open-Label, Multicenter, Prospective Study of Paclitaxel Plus Capecitabine with Subsequent Capecitabine Maintenance Therapy As First-Line Treatment for Metastatic or Recurrent Gastric Cancer

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis

The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens

Paclitaxel Enhances Tumoricidal Potential of TRAIL Via Inhibition of MAPK in Resistant Gastric Cancer Cells.

PD-L1 Monoclonal Antibody-Decorated Nanoliposomes Loaded with Paclitaxel and P-gp Transport Inhibitor for the Synergistic Chemotherapy Against Multidrug Resistant Gastric Cancers.

Establishment and characterization ofpaclitaxel-resistant gastric cancer cell HGC-27/PTX

Antitumor Activity of Selective MEK1/2 Inhibitor AZD6244 in Combination with PI3K/mTOR Inhibitor BEZ235 in Gefitinib-Resistant NSCLC Xenograft Models

Cancer Therapy : Preclinical Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ 235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using Nvp-Bez235 As A Novel Therapeutic Approach in Human Ovarian Carcinoma

The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines

Geridonin and Paclitaxel Act Synergistically to Inhibit the Proliferation of Gastric Cancer Cells Through ROS-mediated Regulation of the PTEN/PI3K/Akt Pathway

Plga Nanoparticle-Based Docetaxel/Ly294002 Drug Delivery System Enhances Antitumor Activities Against Gastric Cancer

Enzyme‐Responsive Branched Glycopolymer‐Based Nanoassembly for Co‐Delivery of Paclitaxel and Akt Inhibitor toward Synergistic Therapy of Gastric Cancer

CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50.

Paclitaxel Sensitizes Gastric Cancer Cells to TRAIL-induced Apoptosis